VTRS(Viatris Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $17.89B | $16.26B | $15.43B | $14.74B | $14.30B |
| 毛利润 | $5.58B | $6.50B | $6.44B | $5.62B | $5.01B |
| 营业利润 | −$34.00M | $1.61B | $766.20M | $10.10M | −$2.66B |
| 净利润 | −$1.27B | $2.08B | $54.70M | −$634.20M | −$3.51B |
| 经营现金流 | $3.02B | $3.00B | $2.90B | $2.30B | $2.32B |
| 自由现金流 | $2.56B | $2.59B | $2.52B | $1.98B | $1.94B |
| 摊薄每股收益 | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 |